Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows from operating activities:
Net income (loss)	$ (76,135,904)	$ (2,548,725)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization – continuing operations	5,102	574,672
Depreciation and amortization – discontinued operations		37,992
Amortization of debt issuance costs		250,000
Share-based compensation	5,141,071
Change in fair value of digital assets	66,501,874
Gain on disposal	(6,019)
Losses on disposal	70
Changes in assets and liabilities:
Accounts receivable	(34,254)	978,029
Inventories	325,798	1,852,604
Prepaid expenses and other current assets	706,642	254,118
Accounts payable	48,801	(450,667)
Accrued expenses and other current liabilities	(1,244,749)	180,856
Discontinued operations		(129,055)
Net cash provided by (used in) operating activities	(4,691,568)	999,824
Cash flows from investing activities:
Purchases of property and equipment – continuing operations		(157)
Purchases of digital assets	(65,910,119)
Purchases of short-term investments	(225,439,152)
Purchase of other investments	(110,599,952)
Proceeds from sale of short-term investments	192,902,626
Repayment of principal under loans held-for-investment	37,646
Purchases of property and equipment – discontinued operations		(44,490)
Net cash used in investing activities	(209,008,951)	(44,647)
Cash flows from financing activities:
Net proceeds from issuance of common stock	165,360,897
Prepayment for share repurchase	(1,000,000)
Net (repayments) borrowings under line of credit	(1,615,000)	(600,000)
Net cash provided by (used in) financing activities	162,745,897	(759,937)
Net decrease in cash and cash equivalents	(50,954,622)	195,240
Cash and cash equivalents, beginning of the period	58,501,108	239,187
Cash and cash equivalents, end of the period	7,546,486	434,427
Supplemental disclosure of cash flow information:
Cash paid for interest	199,629	375,637
Cash paid for income taxes
Accrued offering costs	3,140,372
Issuance of common stock to vendors for settlement of liabilities		$ 143,201